Pharmacological exploitation of the α1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation

Journal of Medicinal Chemistry

Volumn 47, Issue 18, 2004, Pages 4453-4462

  Shaw, Yeng Jeng ^a   Yang, Ya Ting ^a   Garrison, Jason B ^b   Kyprianou, Natasha ^b   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (BIPHENYL 4 SULFONYL)PIPERAZINE 1 YL] 6,7 DIMETHOXYQUINAZOLIN 4 YLAMINE; 2 [4 (BIPHENYL 4 SULFONYL)PIPERAZINE 1 YL] 6,7 DIPROPOXYQUINAZOLIN 4 YLAMINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION; CELL DIVISION; CHEMISTRY; DRUG EFFECT; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SYNTHESIS;

ADRENERGIC ALPHA-ANTAGONISTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DOXAZOSIN; ENZYME ACTIVATION; HUMANS; INHIBITORY CONCENTRATION 50; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042754728     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049752k     Document Type: Article

References (18)

1. Kirby, R. S.; Pool, J. L. Alpha Adrenoceptor Blockade in the Treatment of Benign Prostatic Hyperplasia: Past, Present and Future. Br. J. Urol. 1997, 80, 521-532.
2. Kyprianou, N.; Jacobs, S. C. Induction of Apoptosis in the Prostate by Alpha1-Adrenoceptor Antagonists: A Novel Effect of "Old" Drugs. Curr. Urol. Rep. 2000, 1, 89-96.
3. Kyprianou, N.; Benning, C. M. Suppression of Human Prostate Cancer Cell Growth by Alpha1-Adrenoceptor Antagonists Doxazosin and Terazosin via Induction of Apoptosis. Cancer Res. 2000, 60, 4550-4555.
4. Kyprianou, N.; Chon, J.; Benning, C. M. Effects of Alpha(1)-Adrenoceptor (alpha(1)-AR) Antagonists on Cell Proliferation and Apoptosis in the Prostate: Therapeutic Implications in Prostatic Disease. Prostate Suppl. 2000, 9, 42-46.
5. Kyprianou, N. Doxazosin and Terazosin Suppress Prostate Growth by Inducing Apoptosis: Clinical Significance. J. Urol. 2003, 169, 1520-1525.
6. Cuellar, D. C.; Rhee, J.; Kyprianou, N. Alpha1-Adrenoceptor Antagonists Radiosensitize Prostate Cancer Cells via Apoptosis Induction. Anticancer Res. 2002, 22, 1673-1679.
7. Cal, C.; Uslu, R.; Gunaydin, G.; Ozyurt, C.; Omay, S. B. Doxazosin: A New Cytotoxic Agent for Prostate Cancer? BJU Int. 2000, 85, 672-675.
8. Anglin, I. E.; Glassman, D. T.; Kyprianou, N. Induction of Prostate Apoptosis by Alpha1-Adrenoceptor Antagonists: Mechanistic Significance of the Quinazoline Component. Prostate Cancer Prostatic Dis. 2002, 5, 88-95.
9. Benning, C. M.; Kyprianou, N. Quinazoline-Derived Alpha1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis via an Alpha1-Adrenoceptor- Independent Action. Cancer Res. 2002, 62, 597-602.
10. Ilio, K. Y.; Park, II.; Pins, M. R.; Kozlowski, J. M.; Lee, C. Apoptotic Activity of Doxazosin on Prostate Stroma in Vitro is Mediated through an Autocrine Expression of TGF-beta1. Prostate 2001, 48, 131-135.
11. Partin, J. V.; Anglin, I. E.; Kyprianou, N. Quinazoline-Based Alpha 1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis via TGF-Beta Signaling and I Kappa B Alpha Induction. Br. J. Cancer 2003, 88, 1615-1621.
12. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular Survival: A Play in Three Akts. Genes Dev. 1999, 13, 2905-2927.
13. Bonni, A.; Brunet, A.; West, A. E.; Datta, S. R.; Takasu, M. A. et al. Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription- Dependent and -Independent Mechanisms. Science 1999, 286, 1358-1362.
14. Meier, R.; Thelen, M.; Hemmings, B. A. Inactivation and Dephosphorylation of Protein Kinase Balpha (PKBalpha) Promoted by Hyperosmotic Stress. EMBO J. 1998, 17, 7294-7303.
15. Kulp, S. K.; Yang, Y. T.; Hung, C. C.; Chen, K. F.; Lai, J. P. et al. 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells. Cancer Res. 2004, 64, 1444-1451.
16. Elliott, H. L.; Meredith, P. A.; Reid, J. L. Pharmacokinetic Overview of Doxazosin. Am. J. Cardiol. 1987, 59, 78G-81G.
17. Yang, C. C.; Lin, H. P.; Chen, C. S.; Yang, Y. T.; Tseng, P. H. et al. Bcl-xL Mediates a Survival Mechanism Independent of the Phosphoinositide 3-Kinase/Akt Pathway in Prostate Cancer Cells. J. Biol. Chem. 2003, 278, 25872-25878.
18. Fry, D. W. Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy: Progression from Reversible to Irreversible Inhibitors. Pharmacol. Ther., 1999, 82, 207-218.